In a “higher for longer” interest rate environment, we believe in owning high-quality stocks with secular tailwinds. Elizabeth (Lizzie) Evans, CFP® discussed Novo Nordisk and the opportunity ahead for obesity drugs on CNBC. As she notes, Goldman Sachs projects that the obesity drug market could be a $100 billion opportunity by 2030.

Click here for full video!